Wanhai Xu (Bosen You)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Renal Cell Carcinoma

Top Venues

Cell death & disease

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Zhang, Enyang Zhao, Zhuolun Li, Weiyang Liu, Jinpeng Wang, Wenbin Hou, Nan Zhang, Yang Yu, Xuedong Li, Wanhai Xu
Hexokinase HK3-mediated O-GlcNAcylation of EP300: a key regulator of PD-L1 expression and immune evasion in ccRCC. Cell death & disease 15 (8) (2024)
Wei Zhang, Enyang Zhao, Zhuolun Li, Weiyang Liu, Jinpeng Wang, Wenbin Hou, Nan Zhang, Yang Yu, Xuedong Li, Wanhai Xu
Hexokinase HK3-mediated O-GlcNAcylation of EP300: a key regulator of PD-L1 expression and immune evasion in ccRCC. Cell death & disease 15 (8) (2024)
Wei Zhang, Enyang Zhao, Zhuolun Li, Weiyang Liu, Jinpeng Wang, Wenbin Hou, Nan Zhang, Yang Yu, Xuedong Li, Wanhai Xu
Hexokinase HK3-mediated O-GlcNAcylation of EP300: a key regulator of PD-L1 expression and immune evasion in ccRCC. Cell death & disease 15 (8) (2024)
Qing Liu, Bosen You, Jia-Lin Meng, Chi-Ping Huang, Guanglu Dong, Ronghao Wang, Fuju Chou, Shan Gao, Chawnshang Chang, Shuyuan Yeh, Wanhai Xu
Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer gene therapy (2022)
Bosen You, Yin Sun, Jie Luo, Keliang Wang, Qing Liu, Ruizhe Fang, Bingmei Liu, Fuju Chou, Ronghao Wang, Jialin Meng, Chi-Ping Huang, Shuyuan Yeh, Chawnshang Chang, Wanhai Xu
Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene 40 (9) (2021)